British Journal of Anaesthesia, 2002, Vol. 89, No. 5 739-746
© 2002 The Board of Management and Trustees of the British Journal of Anaesthesia
Laboratory Investigations |
Neuroprotective and neurotoxic properties of the ‘inert’ gas, xenon
,*,1,2,1,21 Magill Department of Anaesthesia, Chelsea and Westminster Hospital and 2 Biophysics Group, The Blackett Laboratory, Imperial College of Science, Technology and Medicine, London, UK
*Corresponding author: Department of Anaesthetics and Intensive Care, Faculty of Medicine, Imperial College, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK Declaration of interest. Professor Maze and Professor Franks are Board members of an Imperial College spin-out company (Potexeon Ltd) that is interested in developing clinical applications for medical gases, including xenon. Both Professor Franks and Professor Maze are paid consultants in this activity. In addition, Air Products have funded, and continue to fund, work in the authors’ laboratories that bears on the actions of xenon as an anaesthetic and neuroprotectant and Air Products has a financial stake in Protexeon Ltd. However, none of the work described in this manuscript was funded by either company.
Background. Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors have been shown not only to have neuroprotective effects but also to exhibit neurotoxic properties. In this study, we used c-Fos, a protein product of an immediate early gene, as a marker of neuronal injury to compare the neuroprotective effects of xenon and the neurotoxic properties of xenon, nitrous oxide, and ketamine, three anaesthetics with NMDA receptor antagonist properties.
Methods. We used an in vivo rat model of brain injury in which N-methyl-DL-aspartic acid (NMA) is injected subcutaneously (s.c.) and c-Fos expression in the arcuate nucleus is used as a measure of injury. To examine the neurotoxic potential of each of the three anaesthetics with NMDA receptor antagonist properties, c-Fos expression in the posterior cingulate and retrosplenial (PC/RS) cortices was measured.
Results. Xenon dose-dependently suppressed NMA-induced c-Fos expression in the arcuate nucleus with an IC50 of 47 (2)% atm. At the highest concentration tested (75% atm) NMA-induced neuronal injury was decreased by as much as that observed with the prototypical NMDA antagonist MK801 (0.5 mg kg–1 s.c.). Both nitrous oxide and ketamine dose-dependently increased c-Fos expression in PC/RS cortices; in contrast, xenon produced no significant effect. If the dopamine receptor antagonist haloperidol was given before either nitrous oxide or ketamine, their neurotoxic effects were eliminated.
Conclusions. Uniquely amongst anaesthetics with known NMDA receptor antagonist action, xenon exhibits neuroprotective properties without co-existing neurotoxicity. The reason why ketamine and nitrous oxide, but not xenon, produce neurotoxicity may involve their actions on dopaminergic pathways.
Br J Anaesth 2002; 89: 739–46
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Saravanan, A. R. Exley, K. Valchanov, N. D. Casey, and F. Falter Impact of xenon anaesthesia in isolated cardiopulmonary bypass on very early leucocyte and platelet activation and clearance: a randomized, controlled study Br. J. Anaesth., December 1, 2009; 103(6): 805 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Chakkarapani, M. Thoresen, C. E. Hobbs, K. Aquilina, X. Liu, and J. Dingley A Closed-Circuit Neonatal Xenon Delivery System: A Technical and Practical Neuroprotection Feasibility Study in Newborn Pigs Anesth. Analg., August 1, 2009; 109(2): 451 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. David, B. Haelewyn, C. Rouillon, M. Lecoq, L. Chazalviel, G. Apiou, J.-J. Risso, M. Lemaire, and J. H. Abraini Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia FASEB J, April 1, 2008; 22(4): 1275 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hobbs, M. Thoresen, A. Tucker, K. Aquilina, E. Chakkarapani, and J. Dingley Xenon and Hypothermia Combine Additively, Offering Long-Term Functional and Histopathologic Neuroprotection After Neonatal Hypoxia/Ischemia Stroke, April 1, 2008; 39(4): 1307 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dingley, C. Hobbs, J. Ferguson, J. Stone, and M. Thoresen Xenon/Hypothermia Neuroprotection Regimes in Spontaneously Breathing Neonatal Rats After Hypoxic-Ischemic Insult: The Respiratory and Sedative Effects Anesth. Analg., March 1, 2008; 106(3): 916 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dingley and R. S. Mason A Cryogenic Machine for Selective Recovery of Xenon from Breathing System Waste Gases Anesth. Analg., November 1, 2007; 105(5): 1312 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sakamoto, S. Nakao, M. Masuzawa, T. Inada, M. Maze, N. P. Franks, and K. Shingu The Differential Effects of Nitrous Oxide and Xenon on Extracellular Dopamine Levels in the Rat Nucleus Accumbens: A Microdialysis Study Anesth. Analg., December 1, 2006; 103(6): 1459 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Bickler and C. S. Fahlman The inhaled anesthetic, isoflurane, enhances Ca2+-dependent survival signaling in cortical neurons and modulates MAP kinases, apoptosis proteins and transcription factors during hypoxia. Anesth. Analg., August 1, 2006; 103(2): 419 - 29, table of contents. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dingley, J. Tooley, H. Porter, and M. Thoresen Xenon Provides Short-Term Neuroprotection in Neonatal Rats When Administered After Hypoxia-Ischemia Stroke, February 1, 2006; 37(2): 501 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D Casey, J. Chandler, D. Gifford, and F. Falter Microbubble production in an in vitro cardiopulmonary bypass circuit ventilated with Xenon Perfusion, May 1, 2005; 20(3): 145 - 150. [Abstract] [PDF]
|
|
|
|
|
|
A. Dinse, K. J. Fohr, M. Georgieff, C. Beyer, A. Bulling, and H. U. Weigt Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones Br. J. Anaesth., April 1, 2005; 94(4): 479 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Sanders, D. Ma, and M. Maze Xenon: elemental anaesthesia in clinical practice Br. Med. Bull., February 22, 2005; 71(1): 115 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gruss, T. J. Bushell, D. P. Bright, W. R. Lieb, A. Mathie, and N. P. Franks Two-Pore-Domain K+ Channels Are a Novel Target for the Anesthetic Gases Xenon, Nitrous Oxide, and Cyclopropane Mol. Pharmacol., February 1, 2004; 65(2): 443 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Sanders, N. P. Franks, and M. Maze Xenon: no stranger to anaesthesia Br. J. Anaesth., November 1, 2003; 91(5): 709 - 717. [Abstract] [Full Text] [PDF]
|
|